FDA Approves Broader Anktiva Use for Bladder Cancer
The FDA approved ImmunityBio’s Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer that has not responded to BCG therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.